1. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
- Author
-
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, and Lip GYH
- Subjects
- Animals, Anti-Inflammatory Agents therapeutic use, Anticoagulants therapeutic use, Antiviral Agents therapeutic use, Betacoronavirus, COVID-19, Coronavirus Infections complications, Coronavirus Infections drug therapy, Glycosaminoglycans therapeutic use, Hemostasis, Humans, Inflammation complications, Inflammation immunology, Pandemics, Platelet Aggregation Inhibitors therapeutic use, Pneumonia, Viral complications, Pneumonia, Viral drug therapy, SARS-CoV-2, Thrombosis complications, Thrombosis immunology, COVID-19 Drug Treatment, Coronavirus Infections immunology, Fibrinolytic Agents therapeutic use, Inflammation drug therapy, Pneumonia, Viral immunology, Thrombosis drug therapy
- Abstract
Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19., Competing Interests: No specific funding was sought or received for this manuscript. A list of Disclosures for co-authors is available online in the Supplementary Material (available in the online version)., (Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2020
- Full Text
- View/download PDF